The solid investment-grade ratings on Amgen Inc. Reflect the strong performance of the company's newer products, the growing diversity of its drug portfolio, and its conservative financial policies. At the same time, the ratings are constrained by uncertainties about Amgen's still relatively narrow drug offering.
Arthur Wong